Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and ...
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act ---- Beginning January 1, 2025, providers can ...